BTG plc grossed £106.3 million (US$160.2 million) in an accelerated book build last week in order to fund the acquisition of two businesses: the targeted therapies division of Nordion Inc. and Ekos Corp. Read More

LONDON – A molecule that is released by breast cancer cells and yet stops the cells from growing appears to have its effect by stimulating an inflammatory immune response. Read More

DUBLIN, Ireland – Trino Therapeutics Ltd., a spinout from Trinity College Dublin (TCD), raised €9 million (US$11.6 million) in a Series A round to move PH46A, an oral, first-in-class indane dimer, into clinical trials in ulcerative colitis. Read More

LONDON – Two of Europe's longest-standing public biotechs are leaving the stage following clinical trial failures, with Agennix AG going into liquidation and Phytopharm plc announcing a reverse merger. Read More

LONDON – The publicly funded UK center set up to accelerate the commercialization of cell therapies has signed its first deal with big pharma, agreeing to work with GlaxoSmithKline plc on a range of research projects and technical and regulatory strategies for getting products to market. Read More

• Flamel Technologies Inc., of Lyon, France, said it exercised its right to regain control of two drugs that use its Trigger lock delivery technology that formerly were being developed in partnership with an undisclosed partner. Trigger Lock is an abuse-resistant technology for long-acting opioid analgesics. Read More